Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150


Inter-observer variability in target delineation increases during adaptive treatment of head-and-neck and lung cancer.

Apolle R, Appold S, Bijl HP, Blanchard P, Bussink J, Faivre-Finn C, Khalifa J, Laprie A, Lievens Y, Madani I, Ruffier A, de Ruysscher D, van Elmpt W, Troost EGC.

Acta Oncol. 2019 Jul 4:1-8. doi: 10.1080/0284186X.2019.1629017. [Epub ahead of print]


Time to Change the Limited-Stage Paradigm for Small Cell Lung Cancer?-In Reply.

Salem A, Faivre-Finn C.

JAMA Oncol. 2019 Jun 20. doi: 10.1001/jamaoncol.2019.1332. [Epub ahead of print] No abstract available.


Influence of tumour laterality on patient survival in non-small cell lung cancer after radiotherapy.

McWilliam A, Vasquez Osorio E, Faivre-Finn C, van Herk M.

Radiother Oncol. 2019 May 9;137:71-76. doi: 10.1016/j.radonc.2019.04.022. [Epub ahead of print]


Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non-small Cell Lung Cancer.

Salem A, Little RA, Latif A, Featherstone AK, Babur M, Peset I, Cheung S, Watson Y, Tessyman V, Mistry H, Ashton G, Behan C, Matthews JC, Asselin MC, Bristow RG, Jackson A, Parker GJM, Faivre-Finn C, Williams KJ, O'Connor JPB.

Clin Cancer Res. 2019 Jul 1;25(13):3818-3829. doi: 10.1158/1078-0432.CCR-18-3932. Epub 2019 May 3.


Prognostic value of circulating tumour cells in limited-stage small cell lung cancer: analysis of the concurrent ONce-daily versus twice-daily RadioTherapy (CONVERT) randomised controlled trial.

Tay RY, Fernández-Gutiérrez F, Foy V, Burns K, Pierce J, Morris K, Priest L, Tugwood J, Ashcroft L, Lindsay CR, Faivre-Finn C, Dive C, Blackhall F.

Ann Oncol. 2019 Apr 24. pii: mdz122. doi: 10.1093/annonc/mdz122. [Epub ahead of print]


Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.

Putora PM, Glatzer M, De Ruysscher D, Faivre-Finn C, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadiuszko R, Felip E, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, Brien MO, Paz Ares L, Peeters S, Pöttgen S, Ramella S, Reck M, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, Slotman BJ.

Radiother Oncol. 2019 Jun;135:74-77. doi: 10.1016/j.radonc.2019.02.010. Epub 2019 Mar 15.


Post-treatment lymphocytopaenia, integral body dose and overall survival in lung cancer patients treated with radical radiotherapy.

Joseph N, McWilliam A, Kennedy J, Haslett K, Mahil J, Gavarraju A, Mistry H, Van Herk M, Faivre-Finn C, Choudhury A.

Radiother Oncol. 2019 Jun;135:115-119. doi: 10.1016/j.radonc.2019.03.008. Epub 2019 Mar 20.


Quantitative evaluation of 4D Cone beam CT scans with reduced scan time in lung cancer patients.

Bryce-Atkinson A, Marchant T, Rodgers J, Budgell G, McWilliam A, Faivre-Finn C, Whitfield G, van Herk M.

Radiother Oncol. 2019 Jul;136:64-70. doi: 10.1016/j.radonc.2019.03.027. Epub 2019 Apr 11.


18F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial.

Manoharan P, Salem A, Mistry H, Gornall M, Harden S, Julyan P, Locke I, McAleese J, McMenemin R, Mohammed N, Snee M, Woods S, Westwood T, Faivre-Finn C.

J Thorac Oncol. 2019 Jul;14(7):1296-1305. doi: 10.1016/j.jtho.2019.03.023. Epub 2019 Apr 16.


Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.

Putora PM, Glatzer M, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadziuszko R, Felip E, Faivre-Finn C, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O'Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Slotman B, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, De Ruysscher D.

Radiother Oncol. 2019 Apr;133:163-166. doi: 10.1016/j.radonc.2018.12.014. Epub 2019 Jan 31.


The advanced radiotherapy network (ART-NET) UK lung stereotactic ablative radiotherapy survey: national provision and a focus on image guidance.

Beasley M, Brown S, McNair H, Faivre-Finn C, Franks K, Murray L, van Herk M, Henry A.

Br J Radiol. 2019 Jun;92(1098):20180988. doi: 10.1259/bjr.20180988. Epub 2019 Apr 24.


Author's Reply to the: Letter to the Editor.

Christodoulou M, Faivre-Finn C.

J Thorac Oncol. 2019 Apr;14(4):e63-e64. doi: 10.1016/j.jtho.2019.01.003. No abstract available.


Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial.

Bayman N, Appel W, Ashcroft L, Baldwin DR, Bates A, Darlison L, Edwards JG, Ezhil V, Gilligan D, Hatton M, Jegannathen A, Mansy T, Peake MD, Pemberton L, Rintoul RC, Snee M, Ryder WD, Taylor P, Faivre-Finn C.

J Clin Oncol. 2019 May 10;37(14):1200-1208. doi: 10.1200/JCO.18.01678. Epub 2019 Mar 28.


Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S.

Ann Oncol. 2019 May 1;30(5):863-870. doi: 10.1093/annonc/mdy474. No abstract available.


Accelerated, Dose escalated, Sequential Chemoradiotherapy in Non-small-cell lung cancer (ADSCaN): a protocol for a randomised phase II study.

Hatton MQF, Lawless CA, Faivre-Finn C, Landau D, Lester JF, Fenwick J, Simões R, McCartney E, Boyd KA, Haswell T, Shaw A, Paul J.

BMJ Open. 2019 Jan 29;9(1):e019903. doi: 10.1136/bmjopen-2017-019903.


Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

Peters S, Dafni U, Boyer M, De Ruysscher D, Faivre-Finn C, Felip E, Garrido P, Girard N, Guckenberger M, Haanen J, Le Pechoux C, Mornex F, Ozsahin M, Paz-Ares L, Planchard D, Raben D, Ramalingam S, Reck M, Smit E, Stahel R, Stenzinger A, Swanton C, Vallone S, Garassino MC.

Ann Oncol. 2019 Feb 1;30(2):161-165. doi: 10.1093/annonc/mdy553. No abstract available.


Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial.

Salem A, Mistry H, Hatton M, Locke I, Monnet I, Blackhall F, Faivre-Finn C.

JAMA Oncol. 2018 Dec 6:e185335. doi: 10.1001/jamaoncol.2018.5335. [Epub ahead of print]


Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial.

Christodoulou M, Blackhall F, Mistry H, Leylek A, Knegjens J, Remouchamps V, Martel-Lafay I, Farré N, Zwitter M, Lerouge D, Pourel N, Janicot H, Scherpereel A, Tissing-Tan C, Peignaux K, Geets X, Konopa K, Faivre-Finn C.

J Thorac Oncol. 2019 Jan;14(1):63-71. doi: 10.1016/j.jtho.2018.09.027. Epub 2018 Oct 31.


ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe.

Rich AL, Baldwin DR, Beckett P, Berghmans T, Boyd J, Faivre-Finn C, Galateau-Salle F, Gamarra F, Grigoriu B, Hansen NG, Hardavella G, Jakobsen E, Jovanovic D, Konsoulova A, Massard G, McPhelim J, Meert AP, Milroy R, Mutti L, Paesmans M, Peake MD, Putora PM, de Ruysscher DKM, Sculier JP, Scherpereel A, Subotic DR, Van Schil P, Blum TG.

Eur Respir J. 2018 Dec 20;52(6). pii: 1800610. doi: 10.1183/13993003.00610-2018. Print 2018 Dec.


The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial).

van Diessen J, De Ruysscher D, Sonke JJ, Damen E, Sikorska K, Reymen B, van Elmpt W, Westman G, Fredberg Persson G, Dieleman E, Bjorkestrand H, Faivre-Finn C, Belderbos J.

Radiother Oncol. 2019 Feb;131:166-173. doi: 10.1016/j.radonc.2018.09.019. Epub 2018 Oct 13.


Prophylactic Cranial Irradiation for Limited-Stage Small-Cell Lung Cancer Patients: Secondary Findings From the Prospective Randomized Phase 3 CONVERT Trial.

Levy A, Le Péchoux C, Mistry H, Martel-Lafay I, Bezjak A, Lerouge D, Padovani L, Taylor P, Faivre-Finn C.

J Thorac Oncol. 2019 Feb;14(2):294-297. doi: 10.1016/j.jtho.2018.09.019. Epub 2018 Oct 4.


Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv192-iv237. doi: 10.1093/annonc/mdy275. No abstract available.


Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M; PACIFIC Investigators.

N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.


Short Communication: Management of patients with extensive-stage small-cell lung cancer treated with radiotherapy: A survey of practice.

Haslett K, De Ruysscher D, Dziadziuszko R, Guckenberger M, Pechoux CL, Nestle U, Slotman B, Faivre-Finn C.

Cancer Treat Res Commun. 2018;17:18-22. doi: 10.1016/j.ctarc.2018.08.004. Epub 2018 Aug 30.


Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie?

Thompson MK, Poortmans P, Chalmers AJ, Faivre-Finn C, Hall E, Huddart RA, Lievens Y, Sebag-Montefiore D, Coles CE.

Br J Cancer. 2018 Aug;119(4):389-407. doi: 10.1038/s41416-018-0201-z. Epub 2018 Jul 31. Review.


Magnetic Resonance Imaging-Guided Radiation Therapy: A Short Strengths, Weaknesses, Opportunities, and Threats Analysis.

van Herk M, McWilliam A, Dubec M, Faivre-Finn C, Choudhury A.

Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1057-1060. doi: 10.1016/j.ijrobp.2017.11.009. No abstract available.


Residual Setup Errors Towards the Heart After Image Guidance Linked With Poorer Survival in Lung Cancer Patients: Do We Need Stricter IGRT Protocols?

Johnson-Hart CN, Price GJ, Faivre-Finn C, Aznar MC, van Herk M.

Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):434-442. doi: 10.1016/j.ijrobp.2018.05.052. Epub 2018 Jun 1.


Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer.

Conibear J, Chia B, Ngai Y, Bates AT, Counsell N, Patel R, Eaton D, Faivre-Finn C, Fenwick J, Forster M, Hanna GG, Harden S, Mayles P, Moinuddin S, Landau D.

BMJ Open. 2018 Apr 17;8(4):e020690. doi: 10.1136/bmjopen-2017-020690. Erratum in: BMJ Open. 2019 May 9;9(5):e020690corr1.


ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer.

Nestle U, De Ruysscher D, Ricardi U, Geets X, Belderbos J, Pöttgen C, Dziadiuszko R, Peeters S, Lievens Y, Hurkmans C, Slotman B, Ramella S, Faivre-Finn C, McDonald F, Manapov F, Putora PM, LePéchoux C, Van Houtte P.

Radiother Oncol. 2018 Apr;127(1):1-5. doi: 10.1016/j.radonc.2018.02.023. Epub 2018 Mar 28.


Are We Ready to Safely Combine Anti-PD-1/PD-L1 with Cranial Irradiation in Non-Small Cell Lung Cancer Patients?

Levy A, Hendriks LE, Faivre-Finn C.

J Thorac Oncol. 2018 Apr;13(4):475-477. doi: 10.1016/j.jtho.2018.02.019. No abstract available.


Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?

Hudson A, Chan C, Woolf D, McWilliam A, Hiley C, O'Connor J, Bayman N, Blackhall F, Faivre-Finn C.

Lung Cancer. 2018 Apr;118:139-147. doi: 10.1016/j.lungcan.2018.02.006. Epub 2018 Feb 14. Review.


BTS guideline for the investigation and management of malignant pleural mesothelioma.

Woolhouse I, Bishop L, Darlison L, de Fonseka D, Edey A, Edwards J, Faivre-Finn C, Fennell DA, Holmes S, Kerr KM, Nakas A, Peel T, Rahman NM, Slade M, Steele J, Tsim S, Maskell NA.

BMJ Open Respir Res. 2018 Feb 14;5(1):e000266. doi: 10.1136/bmjresp-2017-000266. eCollection 2018.


Response to a Request for Clarification Regarding the Advanced Radiotherapy Technologies Network (ART-NET).

Faivre-Finn C, Harrington K.

Clin Oncol (R Coll Radiol). 2018 Jun;30(6):391-393. doi: 10.1016/j.clon.2018.01.021. Epub 2018 Mar 2. No abstract available.


Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey.

Levy A, Faivre-Finn C, Hasan B, De Maio E, Berghoff AS, Girard N, Greillier L, Lantuéjoul S, O'Brien M, Reck M, Dingemans AC, Novello S, Berghmans T, Besse B, Hendriks L; Young Investigators EORTC Lung Cancer Group (YI EORTC LCG).

Eur J Cancer. 2018 Apr;93:37-46. doi: 10.1016/j.ejca.2018.01.067. Epub 2018 Feb 21.


Current Practice of Whole Brain Radiotherapy in Metastatic Non-small Cell Lung Cancer.

Clarke S, Faivre-Finn C, Woolf DK.

Clin Oncol (R Coll Radiol). 2018 Apr;30(4):e40. doi: 10.1016/j.clon.2018.01.013. Epub 2018 Feb 12. No abstract available.


British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma.

Woolhouse I, Bishop L, Darlison L, De Fonseka D, Edey A, Edwards J, Faivre-Finn C, Fennell DA, Holmes S, Kerr KM, Nakas A, Peel T, Rahman NM, Slade M, Steele J, Tsim S, Maskell NA.

Thorax. 2018 Mar;73(Suppl 1):i1-i30. doi: 10.1136/thoraxjnl-2017-211321. No abstract available.


Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging.

Salem A, Mistry H, Backen A, Hodgson C, Koh P, Dean E, Priest L, Haslett K, Trigonis I, Jackson A, Asselin MC, Dive C, Renehan A, Faivre-Finn C, Blackhall F.

Clin Lung Cancer. 2018 May;19(3):239-248.e7. doi: 10.1016/j.cllc.2017.12.002. Epub 2017 Dec 11.


Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms.

Kordbacheh T, Honeychurch J, Blackhall F, Faivre-Finn C, Illidge T.

Ann Oncol. 2018 Feb 1;29(2):301-310. doi: 10.1093/annonc/mdx790. Review.


A method to combine target volume data from 3D and 4D planned thoracic radiotherapy patient cohorts for machine learning applications.

Johnson C, Price G, Khalifa J, Faivre-Finn C, Dekker A, Moore C, van Herk M.

Radiother Oncol. 2018 Feb;126(2):355-361. doi: 10.1016/j.radonc.2017.11.015. Epub 2017 Dec 6.


Benefit of using motion compensated reconstructions for reducing inter-observer and intra-observer contouring variation for organs at risk in lung cancer patients.

McWilliam A, Lee L, Harris M, Sheikh H, Pemberton L, Faivre-Finn C, van Herk M.

Radiother Oncol. 2018 Feb;126(2):333-338. doi: 10.1016/j.radonc.2017.11.021. Epub 2017 Dec 5.


Magnetic resonance imaging in precision radiation therapy for lung cancer.

Bainbridge H, Salem A, Tijssen RHN, Dubec M, Wetscherek A, Van Es C, Belderbos J, Faivre-Finn C, McDonald F; lung tumour site group of the international Atlantic MR-Linac Consortium.

Transl Lung Cancer Res. 2017 Dec;6(6):689-707. doi: 10.21037/tlcr.2017.09.02. Review.


CONVERTed or not: what are the barriers to implementing the evidence? - Author's reply.

Faivre-Finn C.

Lancet Oncol. 2017 Nov;18(11):e628. doi: 10.1016/S1470-2045(17)30800-8. Epub 2017 Oct 31. No abstract available.


Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges ahead.

Ulahannan D, Khalifa J, Faivre-Finn C, Lee SM.

Ann Oncol. 2017 Dec 1;28(12):2923-2931. doi: 10.1093/annonc/mdx481. Review.


A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy.

Jochems A, El-Naqa I, Kessler M, Mayo CS, Jolly S, Matuszak M, Faivre-Finn C, Price G, Holloway L, Vinod S, Field M, Barakat MS, Thwaites D, de Ruysscher D, Dekker A, Lambin P.

Acta Oncol. 2018 Feb;57(2):226-230. doi: 10.1080/0284186X.2017.1385842. Epub 2017 Oct 14.


Is it time to convert the frequency of radiotherapy in small-cell lung cancer? - Authors' reply.

Faivre-Finn C, Ryder WD, Blackhall F.

Lancet Oncol. 2017 Oct;18(10):e556. doi: 10.1016/S1470-2045(17)30611-3. No abstract available.


The CONVERT Trial: Interpretation, Journey and Lessons Learnt.

Faivre-Finn C, Falk S, Blackhall F.

Clin Oncol (R Coll Radiol). 2017 Dec;29(12):811-813. doi: 10.1016/j.clon.2017.09.002. Epub 2017 Sep 19. No abstract available.


Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome.

Salem A, Asselin MC, Reymen B, Jackson A, Lambin P, West CML, O'Connor JPB, Faivre-Finn C.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx160. Review.


The clinical utility of circulating tumour cells in patients with small cell lung cancer.

Foy V, Fernandez-Gutierrez F, Faivre-Finn C, Dive C, Blackhall F.

Transl Lung Cancer Res. 2017 Aug;6(4):409-417. doi: 10.21037/tlcr.2017.07.05. Review.


Radiation dose to heart base linked with poorer survival in lung cancer patients.

McWilliam A, Kennedy J, Hodgson C, Vasquez Osorio E, Faivre-Finn C, van Herk M.

Eur J Cancer. 2017 Nov;85:106-113. doi: 10.1016/j.ejca.2017.07.053. Epub 2017 Sep 11.


Developing and Validating a Survival Prediction Model for NSCLC Patients Through Distributed Learning Across 3 Countries.

Jochems A, Deist TM, El Naqa I, Kessler M, Mayo C, Reeves J, Jolly S, Matuszak M, Ten Haken R, van Soest J, Oberije C, Faivre-Finn C, Price G, de Ruysscher D, Lambin P, Dekker A.

Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):344-352. doi: 10.1016/j.ijrobp.2017.04.021. Epub 2017 Apr 24.

Supplemental Content

Loading ...
Support Center